CN115803342A - 抗TGFβ抗体及其治疗用途 - Google Patents

抗TGFβ抗体及其治疗用途 Download PDF

Info

Publication number
CN115803342A
CN115803342A CN202180049397.1A CN202180049397A CN115803342A CN 115803342 A CN115803342 A CN 115803342A CN 202180049397 A CN202180049397 A CN 202180049397A CN 115803342 A CN115803342 A CN 115803342A
Authority
CN
China
Prior art keywords
seq
amino acid
antigen binding
binding protein
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180049397.1A
Other languages
English (en)
Chinese (zh)
Inventor
L.M.伯杰隆
G.F.巴默特
H.L.坎珀斯
S.A.M.赖特勒
C.J.斯特里策尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Zoetis Services LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services LLC filed Critical Zoetis Services LLC
Publication of CN115803342A publication Critical patent/CN115803342A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180049397.1A 2020-06-08 2021-06-08 抗TGFβ抗体及其治疗用途 Pending CN115803342A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063036092P 2020-06-08 2020-06-08
US63/036,092 2020-06-08
PCT/US2021/036347 WO2021252455A1 (en) 2020-06-08 2021-06-08 ANTI-TGFβ ANTIBODIES AND THERAPEUTIC USES THEREOF

Publications (1)

Publication Number Publication Date
CN115803342A true CN115803342A (zh) 2023-03-14

Family

ID=76708478

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180049397.1A Pending CN115803342A (zh) 2020-06-08 2021-06-08 抗TGFβ抗体及其治疗用途

Country Status (13)

Country Link
US (1) US20220119513A1 (https=)
EP (1) EP4161654A1 (https=)
JP (1) JP7798805B2 (https=)
KR (1) KR20230022974A (https=)
CN (1) CN115803342A (https=)
AU (1) AU2021287868A1 (https=)
BR (1) BR112022024195A2 (https=)
CA (1) CA3186707A1 (https=)
CO (1) CO2023000068A2 (https=)
DK (1) DK202370008A1 (https=)
MX (1) MX2022015609A (https=)
PH (1) PH12022500030A1 (https=)
WO (1) WO2021252455A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025055383A1 (zh) * 2023-09-15 2025-03-20 成都蓉生药业有限责任公司 一种抗TGFβ的人源化纳米抗体

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230038522A (ko) 2020-07-10 2023-03-20 인베티엑스 인코포레이티드 고양이에서 치료제의 반감기를 증가시키기 위한 조성물 및 사용 방법
MX2023003624A (es) 2020-09-28 2023-04-11 Zoetis Services Llc Variantes de anticuerpos caninos.
CA3232382A1 (en) * 2021-09-27 2023-03-30 Zoetis Services Llc Anti- tgf.beta.1,2,3 antibodies and therapeutic uses thereof
WO2024145280A2 (en) 2022-12-27 2024-07-04 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
US20240209096A1 (en) 2022-12-27 2024-06-27 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
AU2024210302A1 (en) 2023-01-20 2025-09-04 Invetx, Inc. Bispecific binding agents for use in companion animals

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101346394A (zh) * 2005-12-23 2009-01-14 伊莱利利公司 TGF-β结合组合物
CN107787329A (zh) * 2015-03-04 2018-03-09 建新公司 以高亲和力、亲和性及特异性结合转化生长因子‑β1的经修饰的IgG抗体
CN107889491A (zh) * 2015-03-04 2018-04-06 建新公司 以高亲和性、亲合力及特异性结合转化生长因子‑β1的scFv‑Fc二聚体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5350576A (en) 1991-09-13 1994-09-27 Mycogen Corporation Bacillus thuringiensis isolates for controlling acarides
US6194167B1 (en) 1997-02-18 2001-02-27 Washington State University Research Foundation ω-3 fatty acid desaturase
MXPA01009363A (es) 1999-03-18 2002-06-04 Merck Patent Gmbh Proteina para bloquear la adhesion de plaquetas.
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
EP1130098A3 (en) 2000-02-29 2003-09-10 Pfizer Products Inc. Mammalian osteoregulins
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
US7261890B2 (en) 2001-12-21 2007-08-28 Idexx Laboratories, Inc. Methods for using canine immunoglobulin variable domains and caninized antibodies
US9518112B2 (en) * 2012-03-08 2016-12-13 Ludwig Institute For Cancer Research Ltd TGF-β1 specific antibodies and methods and uses thereof
LT2971048T (lt) * 2013-03-11 2019-02-25 Genzyme Corporation Inžineriniu būdu gauti anti-tgf-beta antikūnai ir antigeną surišantys fragmentai
TWI787230B (zh) * 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
WO2018208670A1 (en) * 2017-05-08 2018-11-15 Trustees Of Tufts College EXTRACELLULAR VESICLES COMPRISING MEMBRANE-TETHERED TGF-β, COMPOSITIONS AND METHODS OF USE THEREOF
CN113613725B (zh) * 2018-11-05 2025-09-23 路德维格癌症研究所有限公司 人源化和变体TGF-β1特异性抗体及其方法和用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101346394A (zh) * 2005-12-23 2009-01-14 伊莱利利公司 TGF-β结合组合物
CN107787329A (zh) * 2015-03-04 2018-03-09 建新公司 以高亲和力、亲和性及特异性结合转化生长因子‑β1的经修饰的IgG抗体
CN107889491A (zh) * 2015-03-04 2018-04-06 建新公司 以高亲和性、亲合力及特异性结合转化生长因子‑β1的scFv‑Fc二聚体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025055383A1 (zh) * 2023-09-15 2025-03-20 成都蓉生药业有限责任公司 一种抗TGFβ的人源化纳米抗体

Also Published As

Publication number Publication date
KR20230022974A (ko) 2023-02-16
CA3186707A1 (en) 2021-12-16
AU2021287868A1 (en) 2022-12-22
CO2023000068A2 (es) 2023-01-16
PH12022500030A1 (en) 2024-02-26
US20220119513A1 (en) 2022-04-21
BR112022024195A2 (pt) 2023-02-07
EP4161654A1 (en) 2023-04-12
DK202370008A1 (en) 2023-01-31
JP7798805B2 (ja) 2026-01-14
MX2022015609A (es) 2023-04-20
WO2021252455A1 (en) 2021-12-16
JP2023530663A (ja) 2023-07-19

Similar Documents

Publication Publication Date Title
CN111819197B (zh) 抗ngf抗体及其方法
KR102828306B1 (ko) 수의학적 용도를 위한 인터류킨-31 단클론성 항체
JP7798805B2 (ja) 抗ＴＧＦβ抗体及びその治療的使用
US9951128B2 (en) Caninized anti-NGF antibodies and methods thereof
KR20190134614A (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
RS66178B1 (sr) Interleukin-31 monoklonalno antitelo
KR102672548B1 (ko) 인터루킨-31에 대한 펩티드 백신
JP2019531284A (ja) Ｐｄ−１結合タンパク質を使用して免疫障害を治療する方法
US20220106391A1 (en) Anti-ngf antibodies and methods of use thereof
KR20160010391A (ko) Cd20 및 cd95에 결합하는 재조합 이중특이성 항체
TW202229337A (zh) 犬抗體變異體
CA3124356A1 (en) Fn14 antibodies and uses thereof
RU2859871C2 (ru) Антитела анти-TGFβ и их терапевтическое применение
US20230192834A1 (en) Anti- tgfb1,2,3 antibodies and therapeutic uses thereof
RU2846726C1 (ru) Варианты собачьих антител
RU2795411C2 (ru) Моноклональные антитела к интерлейкину-31 для ветеринарного применения
RU2786441C2 (ru) Пептидные вакцины против интерлейкина-31

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination